|
|
Article: FDA Approves Advair Diskus(R) 100/50 mcg (fluticasone propionate 100mcg and salmeterol 50mcg inhalation powder) for Children Four to Eleven; First and Only Product Indicated for Children that Treats the Two Main Components of Asthma - Airway Inflammation and Bronchoconstriction.
- Article from:
- PR Newswire
- Article date:
- April 22, 2004
|
Copyright informationCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) approved the use of Advair 100/50 in children four years to eleven years of age with asthma who are symptomatic on inhaled corticosteroid therapy alone. Advair contains an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA) and is the only long-term preventative product that treats the two main components of asthma - airway inflammation and bronchoconstriction. According to the National Institutes of Health's treatment guidelines, an ICS in conjunction with a LABA is a preferred treatment for patients who still have symptoms while taking low dose ICS.
"Advair is a ...
Related newspaper, magazine, and journal articles:
|